FHD-286
Relapsed/Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Key Facts
About Foghorn Therapeutics
Foghorn Therapeutics is developing a new class of precision medicines based on its deep understanding of the chromatin regulatory system. Its platform enables the discovery of selective inhibitors of chromatin regulatory complexes, such as the BAF complex, to treat cancers and other serious diseases with high unmet need. The company has advanced multiple candidates into clinical development, including FHD-286 and FHD-609, and has established strategic collaborations with major pharmaceutical partners like Loxo Oncology at Lilly and Merck. Foghorn aims to translate its novel biology insights into transformative therapies for patients.
View full company profileAbout Foghorn Therapeutics
Foghorn Therapeutics is developing a new class of precision medicines based on its deep understanding of the chromatin regulatory system. Its platform enables the discovery of selective inhibitors of chromatin regulatory complexes, such as the BAF complex, to treat cancers and other serious diseases with high unmet need. The company has advanced multiple candidates into clinical development, including FHD-286 and FHD-609, and has established strategic collaborations with major pharmaceutical partners like Loxo Oncology at Lilly and Merck. Foghorn aims to translate its novel biology insights into transformative therapies for patients.
View full company profile